{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/hyponatraemia/","result":{"data":{"firstChapter":{"id":"2d0342b8-1d8f-5b76-af1d-5c62137a465c","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field d96cd269-4a50-4c12-9a82-a701015e2820 --><h1>Hyponatraemia: Summary</h1><!-- end field d96cd269-4a50-4c12-9a82-a701015e2820 -->","htmlStringContent":"<!-- begin item d939f520-bf63-4d26-84c6-a701015e2820 --><!-- begin field b9fca8c7-62f7-4189-874f-a701015e2820 --><ul><li>Hyponatraemia is defined as a serum sodium concentration of less than 135 mmol/L.</li><li>It is the most common electrolyte disorder encountered in clinical practice and is usually an incidental finding on routine blood tests.</li><li>The severity of hyponatraemia can be classified as:<ul><li>Mild — serum sodium concentration 130–135 mmol/L.</li><li>Moderate — serum sodium concentration 125–129 mmol/L.</li><li>Severe — serum sodium concentration less than 125 mmol/L.</li></ul></li><li>The rate of onset of hyponatraemia can be classified as:<ul><li>Acute — duration of less than 48 hours.</li><li>Chronic — duration of 48 hours or more.</li></ul></li><li>The cause of hyponatraemia is often multifactorial. Common causes include:<ul><li>Medications (most commonly thiazide diuretics).</li><li>Syndrome of inappropriate antidiuresis.</li><li>Underlying medical conditions (such as heart failure, kidney disease, and liver disease).</li></ul></li><li>Most people with hyponatraemia are asymptomatic, particularly if it is mild and has developed slowly. When symptoms are present, they are often non-specific and are related to both the severity of the hyponatraemia and its rate of onset.<ul><li>Rapid changes in serum sodium levels or severe hyponatraemia can cause symptoms of vomiting, headache, drowsiness, seizures, coma, and cardio-respiratory arrest.</li><li>Chronic hyponatraemia can lead to increased risk of falls, bone fractures, osteoporosis, gait instability, and concentration and cognitive deficits.</li></ul></li><li>Assessment of a person with hyponatraemia involves taking a focused history, determining the person’s volume status, and arranging appropriate investigations (including serum and urine osmolality, and urinary sodium concentration) to help identify the cause of hyponatraemia and guide management. After the initial identification of hyponatraemia, serum sodium measurement should be repeated (timescale dependant on clinical judgement) to exclude a rapidly decreasing serum sodium concentration, which will require admission to hospital.</li><li>If the person has severe or symptomatic hyponatraemia, admission to hospital for urgent treatment should be arranged.</li><li>If the person has asymptomatic, moderate hyponatraemia, specialist advice from an endocrinologist should be sought regarding the need for admission or referral.</li><li>If the person has asymptomatic, mild hyponatraemia, the underlying cause of hyponatraemia should be sought in primary care (if possible and appropriate).<br><ul><li>If the person has an acute illness that may be contributing to the hyponatraemia, it should be treated and the serum sodium concentration rechecked after 2 weeks.</li><li>Medications that may be contributing to the hyponatraemia should be stopped if appropriate and the serum sodium concentration rechecked after 2 weeks.</li></ul></li></ul><!-- end field b9fca8c7-62f7-4189-874f-a701015e2820 --><!-- end item d939f520-bf63-4d26-84c6-a701015e2820 -->","topic":{"id":"0a0a0516-fca2-530d-88cd-096861572e3a","topicId":"560440de-b2ae-4ea7-9fb2-a701015e193f","topicName":"Hyponatraemia","slug":"hyponatraemia","aliases":[],"chapters":[{"id":"2d0342b8-1d8f-5b76-af1d-5c62137a465c","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"94ef9729-defa-5118-80c3-603843005f8a","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"0e655e55-4b6c-5ca3-9d0a-bcf5afa498d8","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"262d0445-6fa5-53ed-8b8c-037da1983e4f","slug":"changes","fullItemName":"Changes"},{"id":"f79882a4-6b50-5264-a45b-2d43249a3418","slug":"update","fullItemName":"Update"}]},{"id":"8705184f-c02d-5cb2-9294-d85860c5d56e","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"815d5ca9-eab9-5381-8a01-784808ab6cc7","slug":"goals","fullItemName":"Goals"},{"id":"85b3dae2-f267-5123-913e-442f138841bb","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"80e3ca36-d509-55eb-a763-7ccfa16bcafa","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e5a45e73-9ef1-5cc7-9cee-cd7c7219e953","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9b557451-4a38-5431-a228-8e1d27043742","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3c76bef5-59b5-5e3e-b95c-72fd0f7370fb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2dda3afa-6384-564b-9938-f26680c7b906","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"c2b54f92-5f73-5871-be34-52c87c49e81f","slug":"definition","fullItemName":"Definition"},{"id":"336f0b50-af95-5811-8819-05ebe4104ffb","slug":"pathophysiology","fullItemName":"Pathophysiology"},{"id":"2f18ae19-5934-5b36-8f56-cfbc5010c984","slug":"causes","fullItemName":"Causes"},{"id":"475e9aa0-653a-537b-988e-7f4bcf86f27a","slug":"incidence-prevelance","fullItemName":"Incidence and prevelance"},{"id":"f9af97ee-3a11-59b0-9533-e9a4ed3f8900","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"8887725e-10a2-544c-8f35-8094785500e3","slug":"complications","fullItemName":"Complications"}]},{"id":"1fb71225-29dc-5a7a-a4e6-edf212ae9225","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"6c1bda17-ccd5-52a4-9299-93f536f69e45","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"abaaf6cd-c698-507a-8fe7-feb15605c044","slug":"assessing-a-person-with-hyponatraemia","fullItemName":"Assessing a person with hyponatraemia"}]},{"id":"3f1780bb-24f2-5fae-a374-4de7113ad17f","slug":"management","fullItemName":"Management","subChapters":[{"id":"bf8b2972-5f8b-587a-935c-8f4a06208987","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"23dd936f-0ccd-5303-9c4d-504c43e5f8c8","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"5b75e52d-5896-50b9-9baf-e0fe2b5acf38","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"6c996d4b-7572-5b4c-8adb-efc4b888b240","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a0a19e6f-1376-5caf-95d6-5492111dbefe","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"73af9656-0aa1-53b8-b41a-855898c14f79","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f9132882-237e-5da1-86ef-fac89422fbc6","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0c67dc74-d944-572d-9995-f93fb7844ef9","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6781f94c-c836-5a66-b9df-5ef91879b82b","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"0a0a0516-fca2-530d-88cd-096861572e3a","topicId":"560440de-b2ae-4ea7-9fb2-a701015e193f","topicName":"Hyponatraemia","slug":"hyponatraemia","aliases":[],"topicSummary":"Hyponatraemia is defined as a serum sodium concentration of less than 135 mmol/L. It is the most commonly encountered electrolyte disorder","lastRevised":"Last revised in November 2020","nextPlannedReviewBy":"2025-11-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2025-11","nextPlannedReviewByDisplay":"November 2025","specialities":[{"id":"aa304738-44fc-5b1d-af3b-42cce5d27663","name":"Endocrine and metabolic","slug":"endocrine-metabolic"},{"id":"f72b3ad6-0501-5364-8469-e48bd9b988b9","name":"Kidney disease and urology","slug":"kidney-disease-urology"}],"chapters":[{"id":"2d0342b8-1d8f-5b76-af1d-5c62137a465c","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"94ef9729-defa-5118-80c3-603843005f8a","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"0e655e55-4b6c-5ca3-9d0a-bcf5afa498d8","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"262d0445-6fa5-53ed-8b8c-037da1983e4f","slug":"changes","fullItemName":"Changes"},{"id":"f79882a4-6b50-5264-a45b-2d43249a3418","slug":"update","fullItemName":"Update"}]},{"id":"8705184f-c02d-5cb2-9294-d85860c5d56e","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"815d5ca9-eab9-5381-8a01-784808ab6cc7","slug":"goals","fullItemName":"Goals"},{"id":"85b3dae2-f267-5123-913e-442f138841bb","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"80e3ca36-d509-55eb-a763-7ccfa16bcafa","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"e5a45e73-9ef1-5cc7-9cee-cd7c7219e953","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9b557451-4a38-5431-a228-8e1d27043742","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3c76bef5-59b5-5e3e-b95c-72fd0f7370fb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"2dda3afa-6384-564b-9938-f26680c7b906","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"c2b54f92-5f73-5871-be34-52c87c49e81f","slug":"definition","fullItemName":"Definition"},{"id":"336f0b50-af95-5811-8819-05ebe4104ffb","slug":"pathophysiology","fullItemName":"Pathophysiology"},{"id":"2f18ae19-5934-5b36-8f56-cfbc5010c984","slug":"causes","fullItemName":"Causes"},{"id":"475e9aa0-653a-537b-988e-7f4bcf86f27a","slug":"incidence-prevelance","fullItemName":"Incidence and prevelance"},{"id":"f9af97ee-3a11-59b0-9533-e9a4ed3f8900","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"8887725e-10a2-544c-8f35-8094785500e3","slug":"complications","fullItemName":"Complications"}]},{"id":"1fb71225-29dc-5a7a-a4e6-edf212ae9225","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"6c1bda17-ccd5-52a4-9299-93f536f69e45","slug":"when-to-suspect","fullItemName":"When to suspect"},{"id":"abaaf6cd-c698-507a-8fe7-feb15605c044","slug":"assessing-a-person-with-hyponatraemia","fullItemName":"Assessing a person with hyponatraemia"}]},{"id":"3f1780bb-24f2-5fae-a374-4de7113ad17f","slug":"management","fullItemName":"Management","subChapters":[{"id":"bf8b2972-5f8b-587a-935c-8f4a06208987","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"23dd936f-0ccd-5303-9c4d-504c43e5f8c8","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"5b75e52d-5896-50b9-9baf-e0fe2b5acf38","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"6c996d4b-7572-5b4c-8adb-efc4b888b240","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a0a19e6f-1376-5caf-95d6-5492111dbefe","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"73af9656-0aa1-53b8-b41a-855898c14f79","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"f9132882-237e-5da1-86ef-fac89422fbc6","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"0c67dc74-d944-572d-9995-f93fb7844ef9","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"6781f94c-c836-5a66-b9df-5ef91879b82b","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"0a0a0516-fca2-530d-88cd-096861572e3a"}},"staticQueryHashes":["3666801979"]}